Trial · NCT00608491
Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)
NCT00608491, Phase 3, Completed, Duke University; results first posted 2013-06-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study). Trials, record NCT00608491. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00608491
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)
- NCT number
- NCT00608491
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 188 participants, actual
- Lead sponsor
- Duke University
- Conditions
- Heart Failure
- Interventions
- Stepped pharmacologic care, Ultrafiltration
- First posted
- 2008-02-06
- Last updated
- 2013-06-24
- Results first posted
- 2013-06-24
Source ClinicalTrials.gov
Registered outcomes70
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Serum Creatinine | Change from Baseline to Day 4 | |
| Primary | Change in Weight | Change from Baseline to Day 4 | |
| Secondary | Change in Glomerular Filtration Rate | Change from Baseline to Day 4 | |
| Secondary | Change in Serum Creatinine | Change from Baseline to Day 7 | |
| Secondary | Change in Glomerular Filtration Rate | Change from Baseline to Day 7 | |
| Secondary | Changes in Weight | Change from Baseline to Day 1 | |
| Secondary | Changes in Weight | Change from Baseline to Day 2 | |
| Secondary | Change in Weight | Change from Baseline to Day 3 | |
| Secondary | Changes in Weight | Change from Baseline to Day 5 | |
| Secondary | Change in Weight | Change from Baseline to Day 6 |
1 to 10 of 70Source ClinicalTrials.gov
See all 70 registered outcomesOutcomes70
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Serum Creatinine | Change from Baseline to Day 4 | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | mg/dL | MEAN |
| SECONDARY | Change in Glomerular Filtration Rate | Change from Baseline to Day 4 | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | mL/min | MEAN |
| SECONDARY | Change in Serum Creatinine | Change from Baseline to Day 7 | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | mg/dL | MEAN |
| SECONDARY | Change in Glomerular Filtration Rate | Change from Baseline to Day 7 | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | mL/min | MEAN |
| SECONDARY | Changes in Weight | Change from Baseline to Day 1 | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | lbs | MEAN |
| SECONDARY | Changes in Weight | Change from Baseline to Day 2 | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | lbs | MEAN |
| SECONDARY | Change in Weight | Change from Baseline to Day 3 | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | lbs | MEAN |
| SECONDARY | Changes in Weight | Change from Baseline to Day 5 | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | lbs | MEAN |
| SECONDARY | Change in Weight | Change from Baseline to Day 6 | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | lbs | MEAN |
| SECONDARY | Cumulative Net Fluid Loss | Randomization through Day 1 | Participants analyzed consisted of those participants who had the endpoint data available to be derived. | mL | MEAN |
1 to 10 of 70Source ClinicalTrials.gov
See all 70 outcomesResults by group140
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Serum Creatinine | Stepped Pharmacologic Care | -0.04 | Standard Deviation 0.53 | mg/dL | |
| Change in Serum Creatinine | Ultrafiltration | 0.23 | Standard Deviation 0.70 | mg/dL | |
| Change in Glomerular Filtration Rate | Stepped Pharmacologic Care | 1.67 | Standard Deviation 10.94 | mL/min | |
| Change in Glomerular Filtration Rate | Ultrafiltration | 0.93 | Standard Deviation 14.60 | mL/min | |
| Change in Serum Creatinine | Stepped Pharmacologic Care | -0.00 | Standard Deviation 0.60 | mg/dL | |
| Change in Serum Creatinine | Ultrafiltration | 0.11 | Standard Deviation 0.89 | mg/dL | |
| Change in Glomerular Filtration Rate | Stepped Pharmacologic Care | 2.06 | Standard Deviation 9.32 | mL/min | |
| Change in Glomerular Filtration Rate | Ultrafiltration | 1.82 | Standard Deviation 13.84 | mL/min | |
| Changes in Weight | Stepped Pharmacologic Care | -3.4 | Standard Deviation 5.2 | lbs | |
| Changes in Weight | Ultrafiltration | -4.4 | Standard Deviation 4.5 | lbs |
1 to 10 of 140Source ClinicalTrials.gov
See all 140 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Stepped Pharmacologic Care | 94 | |
| Overall Study | STARTED | Ultrafiltration | 94 | |
| Overall Study | COMPLETED | Stepped Pharmacologic Care | 73 | |
| Overall Study | COMPLETED | Ultrafiltration | 72 | |
| Overall Study | NOT COMPLETED | Stepped Pharmacologic Care | 21 | |
| Overall Study | NOT COMPLETED | Ultrafiltration | 22 |
Source ClinicalTrials.gov
Adverse events42
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Anaemia | Blood and lymphatic system disorders | Stepped Pharmacologic Care | 5 | 94 | |
| serious | Anaemia | Blood and lymphatic system disorders | Ultrafiltration | 6 | 94 | |
| serious | Heparin-Induced Thrombocytopenia | Blood and lymphatic system disorders | Stepped Pharmacologic Care | 0 | 94 | |
| serious | Heparin-Induced Thrombocytopenia | Blood and lymphatic system disorders | Ultrafiltration | 1 | 94 | |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | Stepped Pharmacologic Care | 0 | 94 | |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | Ultrafiltration | 1 | 94 | |
| serious | Acute Coronary Syndrome | Cardiac disorders | Stepped Pharmacologic Care | 0 | 94 | |
| serious | Acute Coronary Syndrome | Cardiac disorders | Ultrafiltration | 1 | 94 | |
| serious | Acute Myocardial Infarction | Cardiac disorders | Stepped Pharmacologic Care | 0 | 94 | |
| serious | Acute Myocardial Infarction | Cardiac disorders | Ultrafiltration | 1 | 94 |
1 to 10 of 42Source ClinicalTrials.gov
See all 42 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Stepped Pharmacologic Care | ||
| Total, all-cause mortality | Ultrafiltration | ||
| Total, other adverse events | Stepped Pharmacologic Care | 0 | 94 |
| Total, other adverse events | Ultrafiltration | 0 | 94 |
| Total, serious adverse events | Stepped Pharmacologic Care | 54 | 94 |
| Total, serious adverse events | Ultrafiltration | 68 | 94 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01HL084904 | Heart Failure Clinical Research Network - DCC | LEE, KERRY L | DUKE UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2006 to 2011 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Stepped Pharmacologic Care vs Ultrafiltration: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00608491
GET https://conductscience.org/api/trials/v1/NCT00608491/registered?page=2